SI9715: MLN9708

LifeSensors SI9715 is a specialized phospho-ubiquitin chain derivative designed to support advanced research in protein regulation and ubiquitin signaling pathways.

$370.00

SKU SI-9715-0005 Categories Proteasome Inhibitors, Small Molecule Modulators and PROTACs

In stock

Product Advantages

Applications

Inhibition of chymotrypsin-like proteasome catalytic activity.

Cellular studies of proteasome inhibition.

MLN9708 is a proteasome inhibitor. Much like Bortezomib, the active form of MLN9708 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.

Info

Purity	>99.6 (HPLC), NMR (conforms)
Quantity	5 mg
Molecular Weight	517.12 Da
Physical State	Lyophilized powder
Solubility	DMSO (103 mg/mL)
CAS No.	1201902-80-8
Storage	4°C, (-20°C Long term). The product can be shipped at room temperature.